ValuEngine upgraded shares of Immune Design (NASDAQ:IMDZ) from a strong sell rating to a sell rating in a report published on Thursday morning.
IMDZ has been the subject of a number of other research reports. Jefferies Group reiterated a buy rating and issued a $8.00 target price on shares of Immune Design in a research report on Thursday, March 15th. Zacks Investment Research upgraded shares of Immune Design from a hold rating to a buy rating and set a $4.50 target price for the company in a research report on Tuesday, March 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Immune Design has a consensus rating of Buy and a consensus price target of $10.63.
Shares of Immune Design stock traded down $0.15 during trading on Thursday, hitting $4.30. 6,421 shares of the stock were exchanged, compared to its average volume of 432,679. The firm has a market capitalization of $214.16 million, a P/E ratio of -2.54 and a beta of 1.88. Immune Design has a 12 month low of $4.35 and a 12 month high of $4.65.
A number of institutional investors and hedge funds have recently made changes to their positions in IMDZ. Schwab Charles Investment Management Inc. grew its holdings in Immune Design by 59.7% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 54,543 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 20,400 shares during the last quarter. BVF Inc. IL bought a new position in Immune Design in the fourth quarter worth $5,732,000. Two Sigma Advisers LP bought a new position in Immune Design in the fourth quarter worth $449,000. Bain Capital Public Equity Management LLC lifted its position in Immune Design by 155.3% in the fourth quarter. Bain Capital Public Equity Management LLC now owns 3,316,769 shares of the biotechnology company’s stock worth $12,935,000 after purchasing an additional 2,017,756 shares during the period. Finally, Franklin Resources Inc. lifted its position in Immune Design by 313.4% in the fourth quarter. Franklin Resources Inc. now owns 3,231,753 shares of the biotechnology company’s stock worth $12,604,000 after purchasing an additional 2,450,000 shares during the period. Hedge funds and other institutional investors own 58.97% of the company’s stock.
About Immune Design
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.